Cost-effectiveness analysis of seven treatments vs sorafenib as first-line therapy for advanced hepatocellular carcinoma in China

doi:10.4251/wjgo.v18.i4.113266

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 4

This Article

(35)

(32)

(0)

(19)

(745)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Systematic Reviews

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastrointest Oncol. Apr 15, 2026; 18(4): 113266
Published online Apr 15, 2026. doi: 10.4251/wjgo.v18.i4.113266

Table 4 Base-case analysis results

Treatment	QALYs PFS	QALYs PD	QALYs total	Cost PFS ($)	Cost PD ($)	Cost total ($)	InCr cost ($)	InCr QALYs	Incremental cost-effectiveness ratio ($/QALY)	Acceptability at willingness-to-pay	Probability optimal
Sorafenib	0.35	0.72	1.07	10380.95	36112.17	46493.12	Reference	Reference	Reference	Reference	11.30%
Avastin plus toripalimab	0.5	0.89	1.39	31707.84	44091.81	75799.65	19276.99	0.32	91582.91	0.00%	0.00%
Lenvatinib	0.73	0.73	1.46	29365.81	36404.3	65770.11	18599.42	0.39	49428.18	48.50%	5.90%
Rivoceranib plus camrelizumab	0.61	0.96	1.57	18063.18	47029.36	65092.54	35766.97	0.5	37198.84	50.60%	14.90%
Sintilimab plus IBI305	0.64	1.04	1.68	31308.96	50951.13	82260.09	44502.34	0.61	58634.38	0.10%	0.00%
Lenvatinib plus pembrolizumab	0.88	0.97	1.85	43623.22	47372.24	90995.46	59589.61	0.78	57054.28	0.60%	0.00%
Avastin plus tecentriq	0.61	1.46	2.07	35119.31	70963.42	106082.73	63425.79	1	59589.61	0.00%	0.00%
Lenvatinib plus transarterial chemoembolization	1.9	0.85	2.75	68059.03	41859.88	109918.91	29306.53	1.68	37753.45	73.50%	67.90%

InCr: Increased; PD: Progressive disease state; PFS: Progression-free survival; QALY: Quality-adjusted life year.

Full Size Table

Citation: Lin ZH, He Y, Xu HX, Xiao L. Cost-effectiveness analysis of seven treatments vs sorafenib as first-line therapy for advanced hepatocellular carcinoma in China. World J Gastrointest Oncol 2026; 18(4): 113266
URL: https://www.wjgnet.com/1948-5204/full/v18/i4/113266.htm
DOI: https://dx.doi.org/10.4251/wjgo.v18.i4.113266

Lin ZH, He Y, Xu HX, Xiao L. Cost-effectiveness analysis of seven treatments vs sorafenib as first-line therapy for advanced hepatocellular carcinoma in China. World J Gastrointest Oncol 2026; 18(4): 113266 [DOI: 10.4251/wjgo.v18.i4.113266]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.